High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation.
about
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's DiseaseIdentification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for TauopathiesSecondary Metabolites in Ramalina terebrata Detected by UHPLC/ESI/MS/MS and Identification of Parietin as Tau Protein InhibitorTracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkersStructural determinants of Tau aggregation inhibitor potencyPreventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau.Reducing agents affect inhibitory activities of compounds: results from multiple drug targets.Differentiating Alzheimer disease-associated aggregates with small molecules.Evaluation of an orthogonal pooling strategy for rapid high-throughput screening of proteases.Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.2,3-Substituted quinoxalin-6-amine analogs as antiproliferatives: a structure-activity relationship studyDiscovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation.Structure and mechanism of action of tau aggregation inhibitors.Aminothienopyridazine inhibitors of tau aggregation: evaluation of structure-activity relationship leads to selection of candidates with desirable in vivo properties.The acetylation of tau inhibits its function and promotes pathological tau aggregation.In vitro aggregation assays using hyperphosphorylated tau protein.Advances in tau-based drug discovery.The many faces of tauIdentification of an aggregation-prone structure of tau.Shapes of the trajectories of 5 major biomarkers of Alzheimer diseaseAminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation.Modulation and detection of tau aggregation with small-molecule ligandsEffects of grape seed proanthocyanidin on Alzheimer's disease in vitro and in vivoNew approaches to the treatment of frontotemporal lobar degeneration.Inhibition of tau polymerization with a cyanine dye in two distinct model systemsIdentification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening.Therapeutic strategies for tau mediated neurodegeneration.Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.Polyphenolic compounds for treating neurodegenerative disorders involving protein misfolding.Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.Screening strategies to identify HSP70 modulators to treat Alzheimer's disease.Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease.Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau.Inhibitory effect of corcin on aggregation of 1N/4R human tau protein in vitro.PENN neurodegenerative disease research - in the spirit of Benjamin Franklin.The Molecular Chaperone Artemin Efficiently Blocks Fibrillization of TAU Protein In Vitro.Tau aggregation inhibitors: the future of Alzheimer's pharmacotherapy?
P2860
Q26739412-863F8184-335A-411D-88DF-A2F3DC94EFF9Q28597211-6CB63A07-0F3E-48DA-9B27-F6B5466B569BQ28828799-A5CAEA08-545C-4D64-9F12-6FA3ABF2F209Q29620245-5B18BEF2-0986-490B-98AA-70F30CAEDDCEQ30353954-30E250B9-C437-41C4-AB8E-19695305DF23Q30649677-250DC98E-5D4C-4C8F-869A-30FB60D0EF20Q31048549-1046830C-F282-4086-8325-A27ED614EF96Q33296123-1094439D-7284-4BA5-87F9-4359C7332BD8Q33348153-58450B6D-126D-42D5-993F-2AB45538CBCDQ33828966-3BEB8D02-236C-4500-80E9-F5993B86E29CQ33837666-3432EB14-A615-402D-8FF6-362A1DD699E5Q33861802-DA636F91-47C9-4D33-9A1E-FA8FEBCCD6F7Q34902096-0F6B80D0-E256-4BE3-8CDC-6199B0DF9557Q35006667-D0F70D10-5BF9-4E74-A0B6-DAE15DD43986Q35059866-6D165C47-2CFB-44C7-97F4-FF75F5D8C142Q35161820-6375DCE9-6F15-41DC-BBA1-D6849BE7BBB4Q35321539-F3D89659-8859-40DF-AFAC-B0CA9383E719Q35870359-AB34F65B-9D3D-41FB-AB81-B437F8EAD6F1Q36337449-41C264B8-977F-4F32-BFFC-197822132773Q36677361-35CE6BB5-AF8B-4DB7-8984-383312A84265Q36779614-34F40DE2-7D0B-47CD-889F-15B24EC8E874Q37050216-12036C85-5F80-49F8-8580-AAD19D08979DQ37204384-3C5CA1F2-8F3F-49AD-83E6-347C6B07994FQ37319294-6E32D80D-7E4E-4DCB-9CBF-573597A55076Q37344041-43702410-D2F4-4A12-B2C2-D997C37A94D9Q37412951-B4946980-3DE3-4A65-9EB8-74BE1DFB76CFQ37550818-29F3098B-188D-424D-90DB-5B86FCBE2639Q37606284-B75BB4E0-1F80-402F-8068-A01FB27C0898Q37775038-489B5293-D59E-4DFF-9E79-FE22A26C6602Q37841631-A16270E7-9192-4C68-93DD-FFE07AEECD2CQ38327692-C356C863-17CD-4E53-B381-2A60C2C7DF3BQ38715233-A58428BB-B34C-4F65-A343-A4DD31050893Q38901388-F75F1B08-5C1E-45D5-BB2D-7D71DDC6C85DQ38983187-0759182C-5341-4EA7-964B-CF456D6B1FE7Q39035486-D653897E-7069-4EC1-BF7D-F216E10B5E6CQ42202910-5D6580F6-100B-4350-B656-4BD58A5730C7Q42414528-08672A81-50C1-451A-83F2-BA12BD4EDC04Q45951320-07610F89-D4CA-41F6-95BB-4E9BAFA937B2Q47137171-EB1D71C4-D8B0-47D7-9118-5FDEB50E5090Q48239696-413A4B6C-1FC0-4D18-9F85-94EB8D449290
P2860
High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
High throughput screening for ...... -induced tau fibril formation.
@ast
High throughput screening for ...... -induced tau fibril formation.
@en
type
label
High throughput screening for ...... -induced tau fibril formation.
@ast
High throughput screening for ...... -induced tau fibril formation.
@en
prefLabel
High throughput screening for ...... -induced tau fibril formation.
@ast
High throughput screening for ...... -induced tau fibril formation.
@en
P2093
P2860
P1476
High throughput screening for ...... -induced tau fibril formation.
@en
P2093
Alex Crowe
Edward Hyde
Virginia M-Y Lee
P2860
P356
10.1016/J.BBRC.2007.03.056
P407
P577
2007-03-19T00:00:00Z